Revolution Medicines, Inc. Shareholders' Equity
Revolution Medicines, Inc. (RVMD) had Shareholders' Equity of $2.61 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-05
- 2026-06-30: Stockholders' Equity Attributable to Parent $2.61B.
- 2026-03-31: Stockholders' Equity Attributable to Parent $1.50B.
- 2025-12-31: Stockholders' Equity Attributable to Parent $1.63B.
- 2025-09-30: Stockholders' Equity Attributable to Parent $1.60B.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $2.61B 10-Q · filed 2026-08-05 |
| 2026-03-31 | $1.50B 10-Q · filed 2026-08-05 |
| 2025-12-31 | $1.63B 10-Q · filed 2026-08-05 |
| 2025-09-30 | $1.60B 10-Q · filed 2025-11-05 |
| 2025-06-30 | $1.87B 10-Q · filed 2026-08-05 |
| 2025-03-31 | $2.08B 10-Q · filed 2026-08-05 |
| 2024-12-31 | $2.27B 10-Q · filed 2026-08-05 |
| 2024-09-30 | $1.57B 10-Q · filed 2025-11-05 |
| 2024-06-30 | $1.62B 10-Q · filed 2025-11-05 |
| 2024-03-31 | $1.73B 10-Q · filed 2025-11-05 |
| 2023-12-31 | $1.83B 10-K · filed 2026-02-25 |
| 2023-09-30 | $837.46M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $930.84M 10-Q · filed 2024-11-06 |
| 2023-03-31 | $952.22M 10-Q · filed 2024-11-06 |
| 2022-12-31 | $685.19M 10-K · filed 2026-02-25 |
| 2022-09-30 | $681.42M 10-Q · filed 2023-11-06 |
| 2022-06-30 | $498.84M 10-Q · filed 2023-11-06 |
| 2022-03-31 | $550.99M 10-Q · filed 2023-11-06 |
| 2021-12-31 | $602.57M 10-K · filed 2025-02-26 |
| 2021-09-30 | $638.20M 10-Q · filed 2022-11-07 |
| 2021-06-30 | $685.01M 10-Q · filed 2022-11-07 |
| 2021-03-31 | $722.58M 10-Q · filed 2022-11-07 |
| 2020-12-31 | $474.68M 10-K · filed 2024-02-26 |
| 2020-09-30 | $505.07M 10-Q · filed 2021-11-10 |
| 2020-06-30 | $360.50M 10-Q · filed 2021-11-10 |
| 2020-03-31 | $385.32M 10-Q · filed 2021-11-10 |
| 2019-12-31 | -$152.57M 10-K · filed 2023-02-27 |
| 2019-09-30 | -$139.45M 10-Q · filed 2020-11-12 |
| 2019-06-30 | -$127.70M 10-Q · filed 2020-11-12 |
| 2019-03-31 | -$118.11M 10-Q · filed 2020-11-12 |
| 2018-12-31 | -$108.42M 10-K · filed 2022-02-28 |
| 2017-12-31 | -$67.72M 10-K · filed 2021-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |